Topics

Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?

08:00 EDT 30th May 2019 | BioPortfolio

Summary of "Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?"

Because it is unknown whether adjusting the dose of sunitinib can benefit patients with pancreatic neuroendocrine neoplasms (Pan-NENs), this retrospective study examined maximum tumor shrinkage rates and prognoses in patients with and without low doses of sunitinib administration.

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of cancer research and clinical oncology
ISSN: 1432-1335
Pages:

Links

DeepDyve research library

PubMed Articles [19459 Associated PubMed Articles listed on BioPortfolio]

Study on the mechanism and intervention strategy of sunitinib induced nephrotoxicity.

Sunitinib is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor activity. Unfortunately, sunitinib kidney toxicity limits its clinical use. Renal injur...

Pitfalls in interventional X-ray organ dose assessment-combined experimental and computational phantom study: application to prostatic artery embolization.

With X-ray radiation protection and dose management constantly gaining interest in interventional radiology, novel procedures often undergo prospective dose studies using anthropomorphic phantoms to d...

The programmed site-specific delivery of the angiostatin sunitinib and chemotherapeutic paclitaxel for highly efficient tumor treatment.

Malignant solid tumors are composed of tumor cells, stromal cells and the complex networks of the tumor microenvironment (TME), which is the underlying cause of the unsatisfactory outcome of conventio...

Mitochondrial oxidative stress plays a critical role in the cardiotoxicity of sunitinib: Running title: Sunitinib and oxidative stress in hearts.

Sunitinib is cardiotoxic, but the mechanisms are not entirely clear. We aimed to enlarge our knowledge about the role of mitochondria in cardiac toxicity of sunitinib in vitro and in vivo. For this re...

Voxel-based dosimetry is superior to mean-absorbed dose approach for establishing dose-effect relationship in targeted radionuclide therapy.

It is becoming evident that patient-individualized dosimetry in targeted radionuclide therapy (TRT) is a must and not a luxury in the era of precision medicine. It's often argued that patient-specific...

Clinical Trials [13096 Associated Clinical Trials listed on BioPortfolio]

Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors

This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin]. Three differ...

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the f...

Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offere...

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

This study is a single arm, pilot study of Sunitinib in patient with RET fusion positive, FGFR2 fusion/FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avat...

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular

An open label multi-site phase II clinical trial of dose escalated sunitinib malate given orally once daily on days 1-28 of each 42-day cycle. Treatment will be continued until there is ei...

Medical and Biotech [MESH] Definitions

A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

The development and application of computational models of human pathophysiology that are individualized to patient-specific data.

The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.

A treatment schedule in which the total dose of radiation is divided into large doses.

Quick Search


DeepDyve research library

Relevant Topics

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...


Searches Linking to this Article